Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$67.93 USD

67.93
210,057

+0.56 (0.83%)

Updated Sep 18, 2025 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

NextGen (NXGN) Introduces New Integrated Care EHR Solution

by Zacks Equity Research

NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty

by Zacks Equity Research

Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.

Zacks Equity Research

3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Zacks Equity Research

Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.

Zacks Equity Research

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.

Zacks Equity Research

Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's Why You Should Retain Universal Health (UHS) Stock Now

by Zacks Equity Research

Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).

Zacks Equity Research

Cardinal Health (CAH) to Extend Medical Distribution Presence

by Zacks Equity Research

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.

Zacks Equity Research

Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View

by Zacks Equity Research

Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.

Zacks Equity Research

Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Henry Schein (HSIC) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.

Zacks Equity Research

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

by Zacks Equity Research

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) robust international performance and strength in its GYN Surgical business.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

LHC Group's (LHCG) Deal With Optum to Boost Value-Based Care

by Zacks Equity Research

LHC Group's (LHCG) deal with Optum is likely to enhance and extend value-based care to patients' homes.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Zacks Equity Research

LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.

Zacks Equity Research

Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Zacks Equity Research

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Zacks Equity Research

Thermo Fisher (TMO) Launches NGS Platform for Clinical Labs

by Zacks Equity Research

Thermo Fisher's (TMO) Ion Torrent Genexus Dx Integrated Sequencer makes next-generation sequencing accessible for all clinical laboratories.

Zacks Equity Research

Reasons to Retain Ecolab (ECL) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Zacks Equity Research

Here's Why You Should Hold on to Inogen (INGN) Stock Now

by Zacks Equity Research

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.

Zacks Equity Research

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.

Zacks Equity Research

Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.